Verax Biomedical renews commercialization agreement
Courtesy
Marlborough’s Verax Biomedical has renewed its commercialization agreement with Fresenius Kabi USA, allowing for the marketing and distribution of a Verax in-vitro diagnostic test that detects bacterial contaminants in donated platelets.
Verax’s product, called the PanGenera Detection test, is the only rapid test cleared by the U.S. Food and Drug Administration for the most common U.S. platelet types, according to the company. It has a disposable test device and components to detect bacterial contaminants’ presence in platelets.
Fresenius Kabi, based in Chicago, manufactures, develops and delivers medical devices and pharmaceuticals.
"Partnering with a leader like Fresenius Kabi is a critical component of our strategy to improve healthcare outcomes by reducing the risk of bacterial contamination in transfused platelets," said Jim Lousararian, CEO of Verax, in a statement.
WBJ Web Partners
Most Recent
Most Recent
0 Comments